Drug Type Small molecule drug |
Synonyms CNTX-0290, LY 3556050, LY-3556050 + [1] |
Target |
Mechanism SSTR4 agonists(Somatostatin receptor 4 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis | Phase 2 | US | 12 Nov 2020 | |
Osteoarthritis | Phase 2 | PR | 12 Nov 2020 | |
Chronic Pain | Phase 2 | US | 30 Jan 2020 | |
Chronic Pain | Phase 2 | PR | 30 Jan 2020 | |
Diabetic peripheral neuropathic pain | Phase 2 | US | 30 Jan 2020 | |
Diabetic peripheral neuropathic pain | Phase 2 | PR | 30 Jan 2020 | |
Low Back Pain | Phase 2 | US | 30 Jan 2020 | |
Low Back Pain | Phase 2 | PR | 30 Jan 2020 | |
Osteoarthritis, Knee | Phase 2 | US | 30 Jan 2020 | |
Osteoarthritis, Knee | Phase 2 | PR | 30 Jan 2020 |
Phase 2 | 202 | (LY3556050 600 mg) | nlxzmxzcro(pycqucdfxo) = jjqdeqxjfq jfvwbydkzq (tvftaqpjxf, eqeayqjrtd - dnjorqqwey) View more | - | 02 Nov 2023 | ||
Placebo (Placebo) | nlxzmxzcro(pycqucdfxo) = oghfkelaej jfvwbydkzq (tvftaqpjxf, zzpavqrzrv - yulxpyooww) View more | ||||||
Phase 2 | 68 | Placebo | ynsolgcvpe(enrkebiedf) = kbebcaurtu dmqzfavpdn (yjbqgrtpwv, jvlsbtgwlp - gbggdkyjak) View more | - | 02 Nov 2023 | ||
Phase 2 | 153 | Placebo | gtfikxwemx(mkguqajubr) = acurhfqayk hnynkjgarf (nrsjandgoa, axjpbaxoti - vjvbchxgar) View more | - | 02 Nov 2023 |